Metabolic Syndrome / Obesity Secondary to Bipolar Disorder

Yes. Under 38 CFR § 3.310(a), any disability proximately caused or chronically worsened by a service-connected condition is itself service-connected. Metabolic Syndrome / Obesity is a documented secondary pairing for Bipolar Disorder with strong medical evidence. A nexus letter from a qualified physician linking the two conditions is the most reliable way to establish this connection.

The gold standard is a private nexus opinion stating — to at least a 50% probability ("at least as likely as not") — that the secondary condition was caused or aggravated by the primary service-connected condition. Peer-reviewed medical literature supporting the physiological mechanism strengthens the nexus. Treatment records documenting the onset or worsening of the secondary condition in temporal relation to the primary are supporting evidence.

The VA rates Metabolic Syndrome / Obesity separately under its own 38 CFR Part 4 diagnostic code, then combines it with Bipolar Disorder and all other service-connected ratings using the combined ratings formula under § 4.25. The formula applies the whole-person concept: a 50% combined existing rating plus a new 30% rating yields 65% (rounded to 70%), not 80%.

38 CFR § 3.310(a) states: "Disability which is proximately due to or the result of a service-connected disease or injury shall be service connected." The aggravation variant under § 3.310(b) applies where the primary condition permanently worsens a pre-existing disability beyond its natural progression. Both standards require a showing of nexus — a medical or scientific link between the primary condition and the secondary.

The medical evidence supporting Metabolic Syndrome / Obesity as secondary to Bipolar Disorder is rated strong. Bipolar disorder promotes metabolic syndrome through both intrinsic pathophysiology and iatrogenic medication effects. The illness itself produces HPA axis dysregulation with cortisol elevations that drive central adiposity, insulin resistance, and dyslipidemia. During depressive episodes, decreased physical activity and increased caloric intake compound metabolic risk. Critically, the medications most effective for bipolar disorder — lithium, valproate, olanzapine, quetiapine — carry substantial metabolic burden: atypical antipsychotics block hypothalamic histamine H1 and serotonin 5-HT2C receptors, increasing appetite and causing rapid weight gain of 5-15 kg within the first year. Olanzapine and clozapine additionally impair pancreatic beta-cell insulin secretion, producing treatment-emergent diabetes in 10-15% of patients.

The VA will not solicit nexus evidence on your behalf for secondary claims. In practice, a written nexus opinion from a private physician or independent medical examiner is essential — the VA's Compensation & Pension (C&P) examiner is not required to produce a favorable nexus opinion, and the VA has discretion to weigh competing opinions. Submitting a private nexus letter at the time of filing is the most reliable strategy.